Abstract
Primary aldosteronism is the most frequent cause of hormonal hypertension. Recent findings support the concept of continuous spectrum of autonomous aldosterone secretion with mild or subclinical forms being even more common than was suspected. Assumptions emerge that a considerable number of low-renin hypertensives might actually have aldosterone overproduction. However, the awareness of the disease and its consequences is still unsatisfactory. Nowadays experts are still trying to manage some unanswered questions and on-going debate on who should be screened for primary aldosteronism and how to do so.
References
(1) Hirsch JS, Hong S. The Demystification of Secondary Hypertension: Diagnostic Strategies and Treatment Algorithms. Curr Treat Options Cardiovasc Med 2019; 21(12):90.
(2) Young WF, Calhoun DA, Lenders JWM, Stowasser M, Textor SC. Screening for Endocrine Hypertension: An Endocrine Society Scientific Statement. Endocr Rev 2017; 38(2):103-22.
(3) Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48(11):2293-300.
(4) Rosenzweig JL, Bakris GL, Berglund LF, Hivert M-F, Horton ES, Kalyani RR, et al. Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2019; 104(9):3939-85.
(5) The SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015 Nov 26; 373(22):2103-2116.
(6) Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 15 maj 2018; 71(19):e127-248.
(7) Tykarski A, Filipiak KJ, Januszewicz A, Litwin M, Narkiewicz K, Prejbisz A, i wsp. Zasady postępowania w nadciśnieniu tętniczym – 2019 rok. Nadciśnienie Tętnicze W Prakt 2019; 5(1):1-86.
(8) Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Kardiol Pol 2019; 77(2):71-159.
(9) Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens 2018; 36(12):2284-309.
(10) Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101(5):1889-916.
(11) Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, et al. Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. J Am Coll Cardiol 2017; 69(14):1811-20.
(12) Baudrand R, Guarda FJ, Fardella C, Hundemer G, Brown J, Williams G, et al. A Continuum of Renin-Independent Aldosteronism in Normotension. Hypertens Dallas Tex 1979 2017; 69(5):950-6.
(13) Freel EM. Primary Aldosteronism or Not Primary Aldosteronism: Is This Now the Question in Normotension? Hypertens Dallas Tex 1979 2017; 69(5):780-1.
(14) Adlin EV. Subclinical Primary Aldosteronism. Ann Intern Med 2017; 167(9):673-4.
(15) Ito Y, Takeda R, Takeda Y. Subclinical primary aldosteronism. Best Pract Res Clin Endocrinol Metab 2012; 26(4):485-95.
(16) Burrello J, Monticone S, Buffolo F, Tetti M, Giraudo G, Schiavone D, et al. Issues in the Diagnosis and Treatment of Primary Aldosteronism. High Blood Press Cardiovasc Prev Off J Ital Soc Hypertens 2016; 23(2):73-82.
(17) Nishikawa T, Omura M, Satoh F, Shibata H, Takahashi K, Tamura N, et al. Guidelines for the diagnosis and treatment of primary aldosteronism – The Japan Endocrine Society 2009. Endocr J. 2011; 58(9):711-21.
(18) Mulatero P, Monticone S, Burrello J, Veglio F, Williams TA, Funder J. Guidelines for primary aldosteronism: uptake by primary care physicians in Europe. J Hypertens 2016; 34(11):2253-7.
(19) Monticone S, Buffolo F, Tetti M, Veglio F, Pasini B, Mulatero P. Genetics in endocrinology: The expanding genetic horizon of primary aldosteronism. Eur J Endocrinol 2018; 178(3):R101-11.
(20) Korzyńska W, Jodkowska A, Gosławska K, Bogunia-Kubik K, Mazur G. Genetic aspects of primary hyperaldosteronism. Adv Clin Exp Med Off 2018; 27(8):1149-1158.
(21) Omata Kei, Satoh Fumitoshi, Morimoto Ryo, Ito Sadayoshi, Yamazaki Yuto, Nakamura Yasuhiro, et al. Cellular and Genetic Causes of Idiopathic Hyperaldosteronism. Hypertension 2018; 72(4):874-80.
(22) Funder JW. Idiopathic Hyperaldosteronism. Hypertension 2018; 72:839-840.
(23) Fernandes-Rosa Fabio Luiz, Williams Tracy Ann, Riester Anna, Steichen Olivier, Beuschlein Felix, Boulkroun Sheerazed, et al. Genetic Spectrum and Clinical Correlates of Somatic Mutations in Aldosterone-Producing Adenoma. Hypertension 2014; 64(2):354-61.
(24) Nishimoto K, Seki T, Kurihara I, Yokota K, Omura M, Nishikawa T, et al. Case Report: Nodule Development From Subcapsular Aldosterone-Producing Cell Clusters Causes Hyperaldosteronism. J Clin Endocrinol Metab 2016; 101(1):6-9.
(25) Nishimoto K, Koga M, Seki T, Oki K, Gomez-Sanchez EP, Gomez-Sanchez CE, et al. Immunohistochemistry of aldosterone synthase leads the way to the pathogenesis of primary aldosteronism. Mol Cell Endocrinol 2017; 441:124-33.
(26) Hayashi T, Zhang Z, Al-Eyd G, Sasaki A, Yasuda M, Oyama M, et al. Expression of aldosterone synthase CYP11B2 was inversely correlated with longevity. J Steroid Biochem Mol Biol 2019; 191:105361.
(27) Ohno Y, Sone M, Inagaki N, Yamasaki T, Ogawa O, Takeda Y, et al. Obesity as a Key Factor Underlying Idiopathic Hyperaldosteronism. J Clin Endocrinol Metab 2018; 103(12):4456-64.
(28) Bhatt PS, Sam AH, Meeran KM, Salem V. The relevance of cortisol co-secretion from aldosterone-producing adenomas. Horm Athens Greece 2019; 18(3):307-13.
(29) Arlt W, Lang K, Sitch AJ, Dietz AS, Rhayem Y, Bancos I, et al. Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. JCI Insight 2017; 2(8).
(30) Hiraishi K, Yoshimoto T, Tsuchiya K, Minami I, Doi M, Izumiyama H, et al. Clinicopathological features of primary aldosteronism associated with subclinical Cushing’s syndrome. Endocr J. 2011;58(7):543-51.
(31) Rossi GP. Does primary aldosteronism exist in normotensive and mildly hypertensive patients, and should we look for it? Hypertens Res 2011; 34(1):43-6.
(32) Lin X, Miao X, Zhu P, Lin F. A Normotensive Patient with Primary Aldosteronism. Case Rep Endocrinol 2017; 2017:5159382.
(33) Médeau V, Moreau F, Trinquart L, Clemessy M, Wémeau J-L, Vantyghem MC, et al. Clinical and biochemical characteristics of normotensive patients with primary aldosteronism: a comparison with hypertensive cases. Clin Endocrinol (Oxf) 2008; 69(1):20-8.
(34) Brown JM, Robinson-Cohen C, Fernandez MAL, Allison MA, Baudrand R, Ix JH, et al. The Spectrum of Subclinical Primary Aldosteronism and Incident Hypertension: A Cohort Study. Ann Intern Med 2017; 167(9):630-41.
(35) Buffolo F, Monticone S, Pecori A, Pieroni J, Losano I, Cavaglià G, et al. The spectrum of low-renin hypertension. Best Pract Res Clin Endocrinol Metab 2020; 101399. doi:10.1016/j.beem.2020.101399. [Epub ahead of print]
(36) Luo Q, Li N, Wang M, Yao X, Heizhati M, Zhang D, et al. Mild primary aldosteronism (PA) followed by overt PA are possibly the most common forms of low renin hypertension: a single-center retrospective study. J Hum Hypertens 2019; https://doi.org/10.1038/s41371-019-0291-y.
(37) Stowasser M, Ahmed AH, Cowley D, Wolley M, Guo Z, McWhinney BC, et al. Comparison of Seated With Recumbent Saline Suppression Testing for the Diagnosis of Primary Aldosteronism. J Clin Endocrinol Metab 2018; 103(11):4113-24.
(38) Burrello J, Monticone S, Losano I, Cavaglià G, Buffolo F, Tetti M, et al. Prevalence of Hypokalemia and Primary Aldosteronism in 5100 Patients Referred to a Tertiary Hypertension Unit. Hypertens Dallas Tex 1979 2020; 75(4):1025-33.
(39) Umakoshi H, Tsuiki M, Takeda Y, Kurihara I, Itoh H, Katabami T, et al. Significance of Computed Tomography and Serum Potassium in Predicting Subtype Diagnosis of Primary Aldosteronism. J Clin Endocrinol Metab 2018; 103(3):900-8.
(40) Wu K-L, Cheng C-J, Sung C-C, Tseng M-H, Hsu Y-J, Yang S-S, et al. Identification of the Causes for Chronic Hypokalemia: Importance of Urinary Sodium and Chloride Excretion. Am J Med 2017; 130(7):846-55.
(41) Markou A, Pappa T, Kaltsas G, Gouli A, Mitsakis K, Tsounas P, et al. Evidence of Primary Aldosteronism in a Predominantly Female Cohort of Normotensive Individuals: A Very High Odds Ratio for Progression into Arterial Hypertension. J Clin Endocrinol Metab 2013; 98(4):1409-16.
(42) Lim YY, Shen J, Fuller PJ, Yang J. Current pattern of primary aldosteronism diagnosis: Delayed and complicated. Aust J Gen Pract 2018; 47(10):712-8.
(43) Ahmed AH, Gordon RD, Ward G, Wolley M, McWhinney BC, Ungerer JP, et al. Effect of Moxonidine on the Aldosterone/Renin Ratio in Healthy Male Volunteers. J Clin Endocrinol Metab 2017; 102(6):2039-43.
(44) Fischer E, Beuschlein F, Bidlingmaier M, Reincke M. Commentary on the Endocrine Society Practice Guidelines: Consequences of adjustment of antihypertensive medication in screening of primary aldosteronism. Rev Endocr Metab Disord 2011; 12(1):43-8.
(45) Williams TA, Reincke M. Management of endocrine disease: Diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited. Eur J Endocrinol 2018; 179(1):R19-29.
(46) Heinrich DA, Adolf C, Quinkler M, Holler F, Lechner B, Nirschl N, et al. Safety of medical adjustment and confirmatory testing in the diagnostic work-up of primary aldosteronism. Eur J Endocrinol 2019; 181(4):421-8.
(47) Heinrich DA, Adolf C, Rump LC, Quack I, Quinkler M, Hahner S, et al. Primary aldosteronism: key characteristics at diagnosis: a trend toward milder forms. Eur J Endocrinol 2018; 178(6):605-11.
(48) Seifarth C, Trenkel S, Schobel H et al. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism. Clin Endocrinol (Oxf) 2002; 57(4):457-65.
(49) Jansen PM, van den Born B-JH, Frenkel WJ, de Bruijne ELE, Deinum J, Kerstens MN, et al. Test characteristics of the aldosterone-to-renin ratio as a screening test for primary aldosteronism. J Hypertens 2014; 32(1):115-126.
(50) Gurgenci T, Geraghty S, Wolley M, Yang J. Screening for primary aldosteronism: How to adjust existing antihypertensive medications to avoid diagnostic errors. Aust J Gen Pract 2020; 49(3):127-31.
(51) Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol 2018; 6(1):51-9.
(52) Griffin, TP, Wall, D, Browne, GA Consider beta-blocker withdrawal when using the aldosterone renin ratio for case detection of primary aldosteronism. Ir Med J 2017; 110:505.
(53) Browne GA, Griffin TP, O’Shea PM, Dennedy MC. β-Blocker withdrawal is preferable for accurate interpretation of the aldosterone-renin ratio in chronically treated hypertension. Clin Endocrinol (Oxf) 2016; 84(3):325-31.
(54) Łebek-Szatańska A, Papierska L. Hormonal testing for primary aldosteronism – new guidelines, old problems. Postępy Nauk Med 2016; 12:915-920.
(55) Sandbaumhüter FA, Haschke M, Vogt B, Bohlender JM. Medication adherence during laboratory workup for primary aldosteronism: pilot study. Patient Prefer Adherence 2018; 12:2449-2455.
(56) Volpe C, Wahrenberg H, Hamberger B, Thorén M. Screening for primary aldosteronism in a primary care unit. J Renin Angiotensin Aldosterone Syst 2013; 14(3):212-9.
(57) Williams TA, Lenders JWM, Mulatero P, Burrello J, Rottenkolber M, Adolf C, et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol 2017; 5(9):689-99.
This work is licensed under a Creative Commons Attribution 4.0 International License.